AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy
- 1 June 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 10 (6) , 412-426
- https://doi.org/10.1634/theoncologist.10-6-412
Abstract
Human immunodeficiency virus (HIV)-infected patients are at increased risk of developing cancer, particularly in the later stages of acquired immune deficiency syndrome (AIDS). Despite the advent of highly active anti-retroviral therapy (HAART), malignancy in this population is a leading cause of morbidity and mortality. Kaposi’s sarcoma (KS) and AIDS-related non-Hodgkin’s lymphoma (ARL) are the most common AIDS-defining malignancies. AIDS-related KS varies from minimal to fulminant disease. Treatment decisions for AIDS-related KS are guided largely by the presence and extent of symptomatic disease. In addition to HAART, excellent treatments exist for both localized disease (topical gel, radiotherapy, and intralesional therapy) and advanced disease (liposomal anthracyclines, paclitaxel). Novel therapies that have become available to treat AIDS-related KS include angiogenesis inhibitors and antiviral agents. ARL comprises a heterogeneous group of malignancies. With the immune restoration afforded by HAART, standard-dose chemotherapies now can be safely administered to treat ARL with curative intent. The role of analogous treatments used in HIV-negative patients, including monoclonal antibodies and autologous stem cell transplantation, requires further clarification in HIV-positive patients. HIV-infected patients also appear to be at increased risk for developing certain non-AIDS-defining cancers, such as Hodgkin’s lymphoma and multiple myeloma. Although the optimal treatment of these neoplasms is at present uncertain, recent advances in chemotherapy, antiretroviral drugs, and supportive care protocols are allowing for more aggressive management of many of the AIDS-related cancers. This article provides an up-to-date review of the epidemiology, pathogenesis, clinical features, and treatment of various AIDS-related malignancies that are likely to be encountered by an oncologist practicing in the current HAART era.Keywords
This publication has 139 references indexed in Scilit:
- Kaposi sarcoma herpesvirus–induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcomaNature Genetics, 2004
- Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma–associated herpesvirusNature Genetics, 2004
- The evidence-based treatment of AIDS-related non-Hodgkin’s lymphomaCancer Treatment Reviews, 2004
- Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphomaCancer, 2003
- AIDS-Related MalignanciesAnnual Review of Medicine, 2003
- Trends in Causes of Death among Persons with Acquired Immunodeficiency Syndrome in the Era of Highly Active Antiretroviral Therapy, San Francisco, 1994–1998The Journal of Infectious Diseases, 2002
- Kaposi's Sarcoma-Associated Herpesvirus-Induced Upregulation of the c-kitProto-Oncogene, as Identified by Gene Expression Profiling, Is Essential for the Transformation of Endothelial CellsJournal of Virology, 2002
- Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin lymphomaCancer, 1999
- Kaposi's sarcoma of internal organs. A multiparameter study of 86 casesCancer, 1995
- Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome: A clinical trial to evaluate efficacy and discomfort associated with injectionJournal of the American Academy of Dermatology, 1993